Sensyne Health PLC Sensyne launches MagnifEye smartphone app
14 January 2021 - 6:00PM
RNS Non-Regulatory
TIDMSENS
Sensyne Health PLC
14 January 2021
Sensyne Health launches MagnifEye smartphone application to
automate the reading and Big Data analysis of lateral flow tests
using deep learning AI
MagnifEye(TM) uses a cloud-based deep learning algorithm to
automate the accurate reading and analysis of lateral flow
diagnostic tests, such as for COVID-19, providing standardised
results in under 2 seconds
Oxford, U.K. 14 January 2021: Sensyne Health plc (LSE: SENS)
("Sensyne" or the "Company" or the "Group"), the Clinical AI
technology company, today announced the launch of MagnifEye, a new
smartphone software application that uses deep machine learning AI
to automate the accurate reading, beyond the human visible
spectrum, and Big Data analysis of lateral flow diagnostic
tests.
MagnifEye draws on research & development at Sensyne over
the past two years in applying deep learning AI to the analysis of
medical images and Big Data analysis of clinical results across
large patient populations. The MagnifEye application was then built
in response to the demand generated by the COVID-19 pandemic for
the accurate and standardised reading of lateral flow tests used
for disease surveillance across large populations and the Big Data
analysis of results in real time. The IP underlying MagnifEye is
the subject of a number of patent applications filed by the
Company.
MagnifEye is marketed as a busines-to-business commercial
product now being offered to lateral flow test manufacturers and
healthcare providers that use lateral flow tests for disease
surveillance across large populations, including in international
markets. MagnifEye can be quickly trained to read and analyse
individual lateral flow tests and has applications in human and
animal health, including cancer, infectious disease and fertility,
as well as plant pathogen and environmental testing. It can be used
as a standalone smartphone application or incorporated into third
party web or native software applications.
The key features and potential benefits of MagnifEye to lateral
flow test manufacturers and healthcare providers that use them
are:
-- Improved accuracy of reading - avoiding human error and
reading beyond the human visible spectrum to reduce the number of
false negative test results
-- Fast response - provides lateral flow test results in under 2 seconds.
-- Reduced risk of fraud - identifying tests that have been tampered with
-- Automated provision of validated test results - securely linking to electronic health records
-- Faster generation of epidemiological insights - using Big
Data analytics with the capacity to analyse the data across very
large populations
-- Improved security - encrypted and securely held data transfer
and storage with links to healthcare providers and public health
officials
-- Flexible - available in iOS, Android or web app formats, as
an API or SDK (software development kit)
Lord (Paul) Drayson PhD FREng, CEO, said: "Applying Clinical AI
to medical imaging has been an important R&D focus for Sensyne
since formation and the Company has developed world-class deep
learning AI capabilities in this area and has a collaboration with
Bayer in the field of machine vision. Diagnostic testing has seen
rapid progress over the past year, accelerated by responses to the
COVID-19 pandemic. We have been working on developing a general
capability to automate the reading of lateral flow tests in
response to demand from commercial test manufacturers and
healthcare providers. We look forward to working with these
potential partners to apply this technology as rapidly as
possible."
-ENDS-
For more information please contact:
Sensyne Health ( www.sensynehealth.com +44 (0) 330 058
) 1845
Lord (Paul) Drayson PhD FREng, Chief Executive
Officer
Michael Norris, Interim Chief Financial
Officer
Dr Richard Pye, Chief Investment Officer
Consilium Strategic Communications +44 (0) 7780 600290
Mary-Jane Elliott
Sukaina Virji
Davide Salvi
sensynehealth@consilium-comms.com
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in
partnership with the NHS to improve patient care and accelerate the
discovery and development of new medicines. Sensyne Health is
listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAAFDFEDFEAA
(END) Dow Jones Newswires
January 14, 2021 02:00 ET (07:00 GMT)
Sensyne Health (LSE:SENS)
Historical Stock Chart
From Apr 2024 to May 2024
Sensyne Health (LSE:SENS)
Historical Stock Chart
From May 2023 to May 2024